ValiRx receives US patent grant for anti-cancer compound
Francesca Morgan
Company News - 2 mins
11:25, 28th November 2019

Biotechnology firm focused on cancer therapeutic development, ValiRx (AIM:VAL) FOLLOW, has received a United States patent grant for the company’s anti-cancer compound, VAL201.

This morning’s announcement follows ValiRx’s earlier statement on 26 June 2019 which saw the US Patent and Trademark Office allow patent claims for the use of VAL201 in the prevention and treatment of metastatic (including prostate) cancer. 

The VAL201 compound is currently undergoing clinical trials for the treatment of prostate cancer and potentially other indications of hormone induced unregulated growth including endometriosis.

The grant, covering one of ValiRx’s largest commercial markets, will provide patent protection to regulate symptoms of metastatic cancer which occurs when the disease spreads from its site of origin to other parts of the body.

Shares in ValiRx were trading 3.85% higher at 0.135p during Thursday morning.

The patent works to prevent the worsening of symptoms, reduce progression and even treat this type or underlying cancer via administration of the VAL201 peptide.

VL201 prevents tumour growth “selectively” by inhibiting the proliferation of tumour cells, the company explained. 

The compound’s clinical trials have so far “met its endpoints very well” allowing ValiRx to use the peptide to demonstrate VL201 as a therapeutic product in what is considered “a poorly-served, yet very substantial commercial market.”

Dr Satu Vainikka, CEO of ValiRx said that the US patent grant represents “a key addition” to the group’s patent coverage and protection for this indication. 

Dr Vainikka further demonstrated the validation of ValiRx’s potential anti-cancer impact under the basis that all primary cancers have the ability to metastasise and spread to other parts of the body at any point.

Follow News & Updates from ValiRx here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist